中国急性大血管闭塞血栓切除术后补救性颅内血管成形术或支架植入术(ANGEL-REBOOT):多中心、开放标签、盲法终点、随机对照试验
ANGEL-REBOOT 是一项在中国36家三级医院开展的多中心、前瞻性、随机、对照、开放标签、盲法终点的临床试验,纳入348例血栓切除术后再通失败或再闭塞风险的急性大血管闭塞性缺血性卒中患者,比较补救性血管成形术或支架植入术与标准治疗。结果显示两组90天改良Rankin量表评分变化无显著差异(共同比值比0.86,95%CI 0.59-1.24,p=0.41),但干预组症状性颅内出血、实质性血肿2型及手术相关动脉夹层风险更高。
要点
- 补救性血管成形术或支架植入术未改善90天临床结局(共同比值比0.86,95%CI 0.59-1.24,p=0.41)。
- 干预组症状性颅内出血8例(5%)vs 对照组1例(1%),实质性血肿2型6例(3%)vs 0例。
- 干预组手术相关动脉夹层24例(14%)vs 对照组5例(3%)。
核心结论
- 在中国血栓切除术后再通失败或再闭塞风险的大血管闭塞性缺血性卒中患者中,补救性血管成形术或支架植入术未改善90天临床结局,且并发症更多。
- 作者认为,替罗非班的超说明书使用可能影响结果及其普遍性,但研究结果不支持在此类患者中额外进行补救性血管成形术或支架植入术。
研究设计与样本
- ANGEL-REBOOT为研究者发起的多中心、前瞻性、随机、对照、开放标签、盲法终点临床试验,在中国19个省份的36家三级医院开展。
- 纳入症状发作24小时内的大血管闭塞性缺血性卒中患者,条件为血栓切除术后再通失败(扩大脑梗死溶栓评分0-2a)或再闭塞风险(残余狭窄>70%)。
- 采用最小化法按1:1随机分配至补救性血管成形术或支架植入术组(干预组)或标准治疗组(对照组),两组均开放标签。
- 两组均可在术中及术后推荐使用替罗非班。
- 主要结局为90天改良Rankin量表评分变化,在意向性治疗人群中评估。
主要发现
- 2021年12月19日至2023年3月17日筛查706例,纳入348例,干预组176例,对照组172例;无患者退出或失访主要结局。
- 患者中位年龄63岁(IQR 55-69),男性258例(74%),女性90例(26%),均为中国人。
- 随机分配后,334例(96%)参与者接受替罗非班动脉内、静脉内或两者兼用。
- 主要结局无组间差异(共同比值比0.86,95%CI 0.59-1.24,p=0.41)。
- 死亡率两组相似(干预组19例[11%] vs 对照组17例[10%]),但干预组症状性颅内出血(8例[5%] vs 1例[1%])、实质性血肿2型(6例[3%] vs 0例)及手术相关动脉夹层(24例[14%] vs 5例[3%])风险更高。
关键数值与推荐
- 主要结局:90天改良Rankin量表评分变化,共同比值比0.86(95%CI 0.59-1.24),p=0.41。
- 症状性颅内出血:干预组8例(5%) vs 对照组1例(1%)。
- 实质性血肿2型:干预组6例(3%) vs 对照组0例。
- 手术相关动脉夹层:干预组24例(14%) vs 对照组5例(3%)。
- 死亡率:干预组19例(11%) vs 对照组17例(10%)。
临床怎么用
- 作者认为,研究结果不支持在血栓切除术后再通失败或再闭塞风险的大血管闭塞性缺血性卒中患者中额外进行补救性血管成形术或支架植入术。
- 原文未据此给出其他推荐。
局限性
- 替罗非班的超说明书使用可能影响结果及其普遍性。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unsuccessful recanalisation or reocclusion after thrombectomy is associated with poor outcomes in patients with large vessel occlusion (LVO) acute ischaemic stroke (LVO-AIS). Bailout angioplasty or stenting (BAOS) could represent a promising treatment for these patients. We conducted a randomised controlled trial with the aim to investigate the safety and efficacy of BAOS following thrombectomy in patients with LVO. METHODS: ANGEL-REBOOT was an investigator-initiated, multicentre, prospective, randomised, controlled, open-label, blinded-endpoint clinical trial conducted at 36 tertiary hospitals in 19 provinces in China. Participants with LVO-AIS 24 h after symptom onset were eligible if they had unsuccessful recanalisation (expanded Thrombolysis In Cerebral Infarction score of 0-2a) or risk of reocclusion (residual stenosis >70%) after thrombectomy. Eligible patients were randomly assigned by the minimisation method in a 1:1 ratio to undergo BAOS as the intervention treatment, or to receive standard therapy (continue or terminate the thrombectomy procedure) as a control group, both open-label. In both treatment groups, tirofiban could be recommended for use during and after the procedure. The primary outcome was the change in modified Rankin Scale score at 90 days, assessed in the intention-to-treat population. Safety outcomes were compared between groups. This trial was completed and registered at ClinicalTrials.gov (NCT05122286). FINDINGS: From Dec 19, 2021, to March 17, 2023, 706 patients were screened, and 348 were enrolled, with 176 assigned to the intervention group and 172 to the control group. No patients withdrew from the trial or were lost to follow-up for the primary outcome. The median age of patients was 63 years (IQR 55-69), 258 patients (74%) were male, and 90 patients (26%) were female; all participants were Chinese. After random allocation, tirofiban was administered either intra-arterially, intravenously, or both in 334 [96%] of 348 participants. No between-group differences were observed in the primary outcome (common odds ratio 0·86 [95% CI 0·59-1·24], p=0·41). Mortality was similar between the two groups (19 [11%] of 176 vs 17 [10%] of 172), but the intervention group showed a higher risk of symptomatic intracranial haemorrhage (eight [5%] of 175 vs one [1%] of 169), parenchymal haemorrhage type 2 (six [3%] of 175 vs none in the control group), and procedure-related arterial dissection (24 [14%] of 176 vs five [3%] of 172). INTERPRETATION: Among Chinese patients with unsuccessful recanalisation or who are at risk of reocclusion after thrombectomy, BAOS did not improve clinical outcome at 90 days, and incurred more complications compared with standard therapy. The off-label use of tirofiban might have affected our results and their generalisability, but our findings do not support the addition of BAOS for such patients with LVO-AIS. FUNDING: Beijing Natural Science Foundation, National Natural Science Foundation of China, National Key R&D Program Beijing Municipal Administration of Hospitals Incubating Program, Shanghai HeartCare Medical Technology, HeMo (China) Bioengineering, Sino Medical Sciences Technology.
引用
- Gao F, Tong X, Jia B, et al. Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial. Lancet Neurol. 2024. PMID: 38914085. doi:10.1016/S1474-4422(24)00186-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。